Sub. H. B. No. 482 Summary

• Prohibits pharmacy benefit managers and health plan issuers from imposing reimbursement rates for prescription drugs to 340B covered entities that are less than the national average drug acquisition cost rate as determined by Centers for Medicare and Medicaid Services, or wholesale acquisition cost if no such rate is available.

• Prohibits health plan issuers from imposing dispensing fees on 340B covered entities that are lower than fees provided to non-340B providers, and prohibits imposing any fee on 340B entities that is not also imposed on non-340B providers.

• Prohibits health plan issuers and Medicaid managed care organizations from discriminating against 340B covered entities in a manner that prevents or interferes with enrollees' choice to receive prescription drugs from 340B covered entities or their contracted pharmacies.

• Requires terminal distributors of dangerous drugs to pay 340B covered entities the full reimbursement amount received from patients and insurers, minus only an agreed-upon fee negotiated in writing.

• Makes any contract provisions violating these requirements unenforceable and requires they be replaced with the dispensing fee or reimbursement rate that applies to non-340B covered entities.